141
Participants
Start Date
November 10, 2014
Primary Completion Date
July 15, 2015
Study Completion Date
September 28, 2015
PF-05089771 150 mg
PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Pregabalin 300 mg
Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
PF-05089771 150 mg + Pregabalin 300 mg
PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
The Medical Research Network, LLC, New York
National Clinical Research - Norfolk, Inc, Norfolk
Eastern Virginia Medical School, Norfolk
Columbus Regional Research Institute, Columbus
Oviedo Medical Research, LLC, Oviedo
MD Clinical, Hallandale
Metabolic Research Institute, Inc, West Palm Beach
PAB Clinical Research, Brandon
Pulmonary Associates of Brandon (PAB), Brandon
Meridien Research, Tampa
Meridien Research, St. Petersburg
Meridien Research, Lakeland
Clinical Physiology Associates, Fort Myers
Meridien Research, Bradenton
Family Care Specialists, Ocala
Renstar Medical Research, Ocala
Meridien Research, Brooksville
Internal Medicine Associates, Tullahoma
Trinity Clinical Research, LLC, Tullahoma
New Phase Research and Development, Knoxville
Clinical Research Advantage, Inc, Evansville
Michigan Head Pain and Neurological Institute, Ann Arbor
KRK Medical Research, Arlington
Nerve and Muscle Center of Texas, Houston
Clinical Research Consortium Arizona, Phoenix
Arizona Research Center, Phoenix
Clinical Research Consortium, Las Vegas
Neuro-Pain Medical Center, Fresno
Rainier Clinical Research Center, Inc, Renton
Brigham and Women's Hospital, Boston
Novex Clinical Research, LLC, New Bedford
Beacon Clinical Research, LLC, Quincy
Lead Sponsor
Pfizer
INDUSTRY